New drug combo tested for Tough-to-Treat head and neck cancers
NCT ID NCT06597565
Summary
This study is testing whether combining two drugs, ACR-368 and a low dose of gemcitabine, can help control advanced head and neck cancer that has returned or spread. It will involve 43 patients who have already tried standard immunotherapy. Participants will receive the drug combination every two weeks for as long as it keeps the cancer from worsening, while doctors monitor how well the tumors respond and track side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.